Piper Sandler elects Stuart M. Essig to board, effective Feb 4, 2026

PIPER SANDLER COMPANIES

Essig was CEO of Integra LifeSciences (1997-2012), growing revenue from ~$15M to $1.6B.
Board expands to 10 directors; Essig appointed to Audit Committee.
Compensation: pro-rated $100K cash retainer, $60K initial equity, $150K annual equity after 2026 meeting.
Essig also serves on IDEXX Laboratories board; previously healthcare M&A banker at Goldman Sachs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.